Starpharma Holdings Limited (ASX: SPL) - ETF Exposure

- Current share price for SPL : $0.750

Starpharma Holdings Limited (SPL) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a biotechnology company with over 20 years of experience in developing dendrimer technology for pharmaceutical applications. Their mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of their unique dendrimer technology.

SPL General Information ⁺

ASX Code	SPL
Website	N/A
Industry/Sector	Pharmaceuticals
Market Cap ($M)	359
SPL Share Price	$0.750
Day High	$0.000
Day Low	$0.000
Last Close	$0.750
SPL Share Price Movement	- ( No change )

Prices as at 16:40, 16 Oct 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to SPL

Starpharma Holdings Limited (SPL) is held across 3 ETFs spanning strategies that include pharmaceuticals exposure . Its weighting in those funds means performance can have an outsized influence - when SPL moves, funds like DACE that hold it can move with it.

For more concentrated exposure, ETFs such as DACE (Dimensional Australian Core Equity (Managed Fund)) allocate about 0% to SPL , while the average exposure across all 3 ETFs that hold it is around 0% .

Top ETF holdings

Dimensional Australian Core Equity (Managed Fund) (DACE) ~ 0%

Last updated: ETF data and holdings as at 18 October 2026

Own SPL directly or through an ETF?

How does holding Starpharma Holdings Limited (SPL) shares directly compare to ETFs that include it?

	SPL Direct	DACE ASX
Holdings	1 company	501 holdings
SPL Weight	100%	0%
Diversification	Single Stock	Broad
Annual Cost	Brokerage only	0.28% p.a.
Approx. Yield	0%	3.18%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not SPL's direct yield. Annual cost uses each ETF's MER.

SPL Exposure on $10,000 investment

How a $10,000 investment in Starpharma Holdings Limited (SPL) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Starpharma Holdings Limited (SPL)	Direct share	$0.750	-11.24%	-$1,124	$8,876
Dimensional Australian Core Equity (Managed Fund) (DACE)	Equity - Australia Strategy	$18.570	0.05%	+$5	$10,005

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Starpharma Holdings Limited (SPL) ETFs

3 ETFs hold Starpharma Holdings Limited (SPL).

ETF	SPL Weight	MER	Yield
Dimensional Australian Core Equity (Managed Fund) (DACE)	0%	0.28%	3.18%

View all 3 ETFs

Starpharma Holdings Limited (SPL) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
Interim	1.5¢	100%	25 Mar 1988	15 Apr 1988	-	-	-

See all dividends from Starpharma Holdings Limited (SPL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Starpharma Holdings Limited (SPL) price-sensitive announcements

SPL - Trading Halt

ASX announced that trading in Starpharma Holdings Limited securities was placed in a tradi

Starpharma Holdings Limited (SPL)
16 Oct 2026 | 9:30 AM

SPL - S&P DJI Announces September 2026 Quarterly Rebalance

The PDF is an S&P Dow Jones Indices index announcement dated 4 September 2026 titled "S&P

Starpharma Holdings Limited (SPL)
4 Sep 2026 | 5:10 PM

SPL - FY26 Key Financial Results and Annual Report

Starpharma Holdings Limited, an innovative biotechnology company specializing in dendrimer

Starpharma Holdings Limited (SPL)
26 Aug 2026 | 9:45 AM

SPL - Preliminary Final Report

Starpharma Holdings Limited's Preliminary Financial Report for the year ended 30 June 2026

Starpharma Holdings Limited (SPL)
26 Aug 2026 | 9:23 AM

Starpharma Holdings Limited (SPL) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Starpharma Holdings Limited (SPL) ORDINARY FULLY PAID	Health Care	$360	Trading Halt	16 Oct 2026 9:30AM	$0.750	$0.750	fallen by 0%
Starpharma Holdings Limited (SPL) ORDINARY FULLY PAID	Health Care	$360	Change in substantial holding	7 Oct 2026 3:03PM	$0.830	$0.750	fallen by 9.64%
Starpharma Holdings Limited (SPL) ORDINARY FULLY PAID	Health Care	$360	Notice of Annual General Meeting/Proxy Form	6 Oct 2026 2:44PM	$0.800	$0.750	fallen by 6.25%
Starpharma Holdings Limited (SPL) ORDINARY FULLY PAID	Health Care	$360	Change of Director's Interest Notice - C Maley	5 Oct 2026 9:33AM	$0.800	$0.750	fallen by 6.25%
Starpharma Holdings Limited (SPL) ORDINARY FULLY PAID	Health Care	$360	Application for quotation of securities - SPL	5 Oct 2026 9:31AM	$0.800	$0.750	fallen by 6.25%
Starpharma Holdings Limited (SPL) ORDINARY FULLY PAID	Health Care	$360	Notification of cessation of securities - SPL	5 Oct 2026 9:25AM	$0.800	$0.750	fallen by 6.25%

SPL Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2028F	C2	-$2.00	-33.30%	0.00%	0.0%
2027F	C2	-$3.00	73.40%	0.00%	0.0%
2026A	-$7.47	-$1.70	-25.80%	0.00%	0.0%

SPL Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F	2026 A	2027 F	2028 F
Clarity Pharmaceuticals Ltd (CU6)	$645M	0.4454	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,433M	-0.7857	0.2462	0.9655	82.4667	66.1724	33.6667	0.00%	1.72%	2.03%
Starpharma Holdings Limited (SPL)	$360M	-0.2575	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%

SPL Directors

Name	Position	Start Date
Ms Cheryl Ann Maley	Chief Executive Officer, Managing Director	8 Jan 2024
Mr David McIntyre	Non-Executive Director	1 Mar 2020
Ms Lynda Cheng	Non-Executive Director	1 Aug 2021
Dr Jeff Davies	Non-Executive Director	1 Apr 2022
Dr Russell Basser	Non-Executive Director	20 Feb 2023
Mr Robert Bain Thomas	Non-Executive Director, Non-Executive Chairman	4 Dec 2013

Starpharma Holdings Limited (SPL) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
11 Aug 2026	DAVIES, Jeff	Issued	Indirect Shares	117,291	$0.570	$66,856.000
11 Aug 2026	BASSER, Russell	Issued	Direct Shares	36,191	$0.570	$20,629.000
11 Aug 2026	CHENG, Lynda	Issued	Indirect Shares	22,741	$0.570	$12,962.000

See all changes in directors' interest & trades for Starpharma Holdings Limited (SPL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

SPL Management

Name	Position
Justin Cahill	Chief Financial Officer,Company Secretary

SPL Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Starpharma Holdings Limited (SPL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
48,480,000 (11.80%)	Allianz SE and the entities
40,050,000 (9.52%)	Rhuroin Pty Ltd
25,799,212 (6.10%)	Ajava Holdings Pty Ltd

SPL Calendar of Events

Date	Event
25 August 2027	Report (Annual)
25 August 2027	Report (Prelim)
17 February 2027	Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us